Last updated on February 2014

Safety Pharmacokinetics and Efficacy of an AT-III Concentrate.


Brief description of study

To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.

Detailed Study Description

This study will be a prospective, unblinded, non-randomized, open-label, multi-center Phase II/III study with 2 segments, i.e. a PK evaluation (Segment I), and an assessment of prophylaxis in surgical interventions and pregnancy/delivery, (Segment II). During the PK segment, the subjects would remain on their current anticoagulation therapy except for subjects on heparin therapy where a wash-out period of at least 5 half lives would be required. In total, 15 subjects with congenital ATIII Deficiency will be enrolled for the PK assessment (Segment I). For Segment II, fifteen episodes will be treated. Recruitment of individual subjects with high risk for venous thrombosis for Segment II of this study is necessary because of the rarity of Antithrombin deficiency in the population.

Clinical Study Identifier: NCT00319228

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jessica Campbell

New York Presbyterian Hospital-Weill Cornell
New York, NY United States
  Connect »

Kathryn L. Moynihan

University of Texas Health Science Center
Houston, TX United States
  Connect »